Asset Purchase and Merger Agreements - Urica Agreement with Crystalys Therapeutics, Inc. ("Crystalys") (Details) - Urica - USD ($) $ in Millions |
1 Months Ended | 3 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2025 |
Jul. 31, 2024 |
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Business Combination [Line Items] | ||||
| Percentage of equity to be held | 35.00% | |||
| Repurchase option liability | $ 2.6 | |||
| Asset Purchase, Royalty And Related Agreements With Crystalis | ||||
| Business Combination [Line Items] | ||||
| Consideration transferred | $ 6.4 | |||
| Assets Sold under Agreements to Repurchase, Accretion Expense | $ 0.7 | |||
| Crystalys Therapeutics, Inc | ||||
| Business Combination [Line Items] | ||||
| Urica's equity position | 15.00% | |||
| Increased carrying amount | $ 1.0 | |||
| Percentage of royalty on future net sales | 3.00% | |||
| Collaboration revenue | $ 0.0 | |||
| Crystalys Therapeutics, Inc | Minimum | ||||
| Business Combination [Line Items] | ||||
| Urica's equity position | 15.00% | |||
| X | ||||||||||
- Definition Amount of share value of anti-dilutive securities received on anti-dilution protection. No definition available.
|
| X | ||||||||||
- Definition Percentage of common stock issued to the company, pursuant to asset acquisition arrangement. No definition available.
|
| X | ||||||||||
- Definition Amount of accretion expense recognized under assets sold under repurchase agreements for the passage of time, typically for liabilities, that have been discounted to their net present values. No definition available.
|
| X | ||||||||||
- Definition Collaboration revenue. No definition available.
|
| X | ||||||||||
- Definition The amount of gain (loss) from reversal of financial obligation. No definition available.
|
| X | ||||||||||
- Definition Percentage of royalty on future net sales granted to the company. No definition available.
|
| X | ||||||||||
- Definition Threshold percentage of fully diluted equity capitalization position in counterparty, to be held by company, until specified amount of equity securities is raised by such counterparty. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|